The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Complement C5 inhibition is the standard of care (SoC) for patients with paroxysmal nocturnal hemoglobinuria (PNH) with significant clinical symptoms. Constant and complete suppression of the terminal complement pathway and the high serum concentration of C5 pose challenges to drug development that...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Röth, Alexander, Nishimura, Jun-ichi, Nagy, Zsolt, Gaàl-Weisinger, Julia, Panse, Jens, Yoon, Sung-Soo, Egyed, Miklos, Ichikawa, Satoshi, Ito, Yoshikazu, Kim, Jin Seok, Ninomiya, Haruhiko, Schrezenmeier, Hubert, Sica, Simona, Usuki, Kensuke, Sicre de Fontbrune, Flore, Soret, Juliette, Sostelly, Alexandre, Higginson, James, Dieckmann, Andreas, Gentile, Brittany, Anzures-Cabrera, Judith, Shinomiya, Kenji, Jordan, Gregor, Biedzka-Sarek, Marta, Klughammer, Barbara, Jahreis, Angelika, Bucher, Christoph, Peffault de Latour, Régis
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2020
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7082616/
https://ncbi.nlm.nih.gov/pubmed/31978221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019003399
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky